Unknown PHASE2 INTERVENTIONAL NCT00116363

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma

Sponsor: Introgen Therapeutics

Conditions Malignant Melanoma Neoplasm Metastasis

Interventions investigational drug INGN 241

Updated 5 times since 2017 Last updated: Mar 28, 2008 Started: Mar 31, 2005 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00116363, this PHASE2 trial focuses on Malignant Melanoma and Neoplasm Metastasis and remains ongoing. Sponsored by Introgen Therapeutics, it has been updated 5 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Introgen Therapeutics
M.D. Anderson Cancer Center

Data source: Introgen Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States